3M™ Integrated Dose by Dose Counter and the 3M™ Nasal Metered Dose Inhaler (MDI)
As inventors of the very first metered dose inhaler (MDI), and being behind the latest MDIs, 3M has been at the forefront of inhalation technology for over 50 years. We take the risk out of commercializing your new product, from start to finish
3M Drug Delivery: Partner with the Expert
3M™ Integrated Dose by Dose Counter and the 3M™ Nasal Metered Dose Inhaler (MDI)
As inventors of the very first metered dose inhaler (MDI), and being behind the latest MDIs, 3M has been at the forefront of inhalation technology for over 50 years. Our experience spans the entire system, from feasibility to selecting the right components – through to commercial scale production.
3M supports pharmaceutical customers globally providing a competitive edge with patient-centered innovations and devices that set our customers apart. Whether you’re looking for a primary contract fill manufacturer, a second source of supply, for cold or pressure fill, our trusted cGMP manufacturing capabilities provide you with reassurance that your product will be available for market.
We take the risk out of commercializing your new product, from start to finish.
Watch our video and learn more
Company name: 3M Drug Delivery Systems
Website: Watch our video and learn more
E-mail:
[email protected]
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
